Skip to main content

Global Epilepsy Market Analysis on Revenue, Gross Margin Driving Essential Factors and Trends

Global Epilepsy Market Research Overview by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), and Regional Analysis, Industry Size, Growth, Technology and Trend – Forecast till 2023
Epilepsy Market Size is Expected to touch a Global worth of USD 9,509.2 million by 2023, exhibiting a CAGR of 8.20% over the forecast period (2018-2023).
Epilepsy has been known as the fourth most prevalent neurological ailment. It is s chronic condition that triggers recurrent and unprovoked seizures. It can affect anyone irrespective of their ages.
World Health Organization records that in 2017, almost 50 million individuals throughout the world suffer from epilepsy, making it one of the most prevalent neurological disorders worldwide. Almost 80% of the people affected by epilepsy have been estimated to live in low- and middle-income economies.
Major Industry Competitive Analysis
Top Epilepsy Industry Key players in the Global Regional Landscapes given as Follows –
  • Eisai Co. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • GW Pharmaceuticals PLC
  • Abbott Laboratories
  • UCB SA
  • LivaNova PLC
  • Medtronic PLC
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline PLC
  • NeuroPace Inc.
  • and Others.
Epilepsy Market Segmentation
The global epilepsy market is segmented by condition, diagnosis & treatment, and end-user.
By condition, the epilepsy market is divided into epilepsy drug resistant/intractable epilepsy and others.
By diagnosis and treatment, the epilepsy market is segmented into diagnosis– imaging devices, blood tests, and others
and treatment- anti-epileptic drugs, neurostimulation devices, brain surgery, ketogenic diet, and others.
By end-user, the epilepsy market include hospitals, clinics, ambulatory surgical centers, diagnostic centers, and others.
Geographically the Epilepsy Market Has been Segmented into Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA). Among all the Americas leads the worldwide market for anti-epilepsy drugs on account of the growing incidents of epilepsy, availability of the advanced technologies, along with the enhanced healthcare infrastructure within the region. Europe holds the second share in the market owing to increasing healthcare outlays, surging healthcare R&D spending by the governing bodies, and rapid patient population.
Browse Complete Premium Report Details at: https://www.marketresearchfuture.com/reports/epilepsy-market-7730
The Asia Pacific region has been the fastest expanding market due to the presence of developing countries like China and India. These regions have large patient population and the countries are putting additional efforts in growing their healthcare outlays. And Middle East and Africa holds the least market share particularly because of the presence of strict government regulations and the poor economic conditions prevailing within the African market.
LIST OF TABLES
TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2015–2023 (USD MILLION)
TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2015–2023 (USD MILLION)
TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2015-2023 (USD MILLION)
TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2015-2023 (USD MILLION)
TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 10 GLOBAL EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 11 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 12 GLOBAL EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
Continued…
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Labels:

Comments

Post a Comment

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibro
3 comments
Read more

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Regional Analysis, Competitive Landscape Forecast to 2023

Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. Market Overview The high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment. The Global  Idiopathic Pulmonary Fibrosis Treatment Market  is expected to register a  CAGR of 12.3%  during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018. The global IPF treatment market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in Sept
2 comments
Read more

Chatbots in Healthcare Market Research Report by Top Industry Vendors and Applications Scenario till 2023

Chatbots in Healthcare Market Overview Healthcare chatbots are programs which assist patients with queries. This reduces the burden on the clinical staff and lets them focus on their jobs. Automation of various workflow processes in the healthcare sector is likely to propel the demand for these virtual assistants. The global Chatbots in Healthcare Market is expected to touch USD 316.85 million by 2023 at 21.10% CAGR over the forecast period (2018-2023), as per Market Research Future (MRFR). It stood at USD 100.46 million in 2017. Rise of chronic diseases coupled with lack of medical experts to handle queries are main drivers of the market. For instance, cancer patients used chatbots to gain rapid assistance regarding medication and their adverse effects.  The  Chatbots in Healthcare Market   Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As,  Sensely, Inc. (U.S.), Your.MD (U.K.), Buoy Healt
2 comments
Read more